An initial review of data from a mid/late stage trial of GenVec's TNFerade for pancreatic cancer demonstrates that it may exceed its goal for improving survival. That news sent GenVec's stock soaring 42 percent in pre-market activity. Analysts were particularly impressed that positive data could accelerate an FDA approval for the therapy, which targets one of the deadliest forms of cancer.
An analysis of the data covering 51 patients followed for up to 18 months demonstrated an increase of overall survival of 42.5 percent when comparing TNFerade combined with a standard therapy against the standard therapy alone.
- here's the release for more information on the trial